[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universitas Muhammadiyah Surakarta\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":127},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,77,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100632591","digital-discharge-planning-to-improve-self-management-in-patients-with-diabetes-mellitus-100632591",false,"NCT07515677","Digital Discharge Planning to Improve Self-Management in Patients With Diabetes Mellitus","Effectiveness of a Digital Discharge Planning Intervention to Improve Self-Management in Patients With Diabetes Mellitus: A Randomized Controlled Trial","DDP-DM","Inclusion Criteria:\n\n* Patients diagnosed with diabetes mellitus.\n* Age 18 years or older.\n* Hospitalized patients who are preparing for discharge.\n* Able to use a smartphone and access the mobile application.\n* Willing to participate and provide informed consent.\n\nExclusion Criteria:\n\n* Patients with severe complications requiring intensive care.\n* Patients with cognitive impairment or severe mental illness that may interfere with participation.\n* Patients who are unable to operate a smartphone or mobile application.\n* Patients who decline to participate in the study.","ALL","18 Years",{"count":20,"type":21},78,"ESTIMATED","INTERVENTIONAL",[24],"NA","Diabetes mellitus is a chronic disease that requires continuous self-management to prevent complications and hospital readmissions. However, discharge planning in many hospitals is often delivered verbally and lacks structured follow-up after patients return home, which may lead to poor self-management behaviors.\n\nThis study aims to evaluate the effectiveness of a digital discharge planning intervention delivered through a mobile application to improve self-management among patients with diabetes mellitus after hospital discharge. The intervention is based on the Chronic Care Model and includes educational materials, reminders, and monitoring tools related to seven dimensions of diabetes self-management.\n\nA randomized controlled trial with a parallel-group design will be conducted among patients with diabetes mellitus. Participants in the intervention group will receive digital discharge planning through a mobile application for 90 days after discharge, while the control group will receive standard discharge planning provided by the hospital. Primary outcomes include patient self-management behavior, while secondary outcomes include glycemic control and hospital readmission within 90 days.",[27],"Diabetes (DM)",[29,30,31,32],"Diabetes Self-Management","Digital Health Intervention","Discharge Planning","Mobile Health","NOT_YET_RECRUITING","2026-04-06",{"date":36,"type":37},"2026-04-13","ACTUAL",{"date":39,"type":21},"2026-04-15",{"date":41,"type":21},"2026-11-30",{"name":43,"class":44},"Universitas Muhammadiyah Surakarta","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":45},"100624662","autogenic-relaxation-and-murottal-therapy-in-hemodialysis-patients-100624662","NCT07412548","Autogenic Relaxation and Murottal Therapy in Hemodialysis Patients","The Effectiveness of Autogenic Relaxation and Surah Ar-Rahman Murottal Therapy on Anxiety, Sleep Quality, and Hemodynamic Parameters in Hemodialysis Patients","AR-MHD","Inclusion Criteria:\n\n1. Patients diagnosed with stage V chronic kidney disease.\n2. Undergoing scheduled hemodialysis at least twice a week for 6 weeks.\n3. Outpatients and aged 18-65 years.\n4. Muslim.\n5. Cooperative and able to communicate verbally.\n6. Willing to be a respondent by signing an informed consent form.\n\nExclusion Criteria:\n\n1. Having a severe heart condition or an unstable critical condition.\n2. Having a severe psychiatric disorder (schizophrenia, major depression).\n3. Having a cognitive, hearing, or speech disorder that impedes communication.\n4. Taking antidepressants, anxiolytics, or neuroleptics that may affect psychological measurement results.","65 Years",{"count":56,"type":21},76,[24],"This quasi-experimental study aims to evaluate the effect of combined autogenic relaxation and Surah Ar-Rahman murottal therapy on anxiety, sleep quality, and hemodynamic parameters in hemodialysis patients. A pretest-posttest control group design will be used involving 76 participants undergoing routine hemodialysis. Participants will be assigned to an intervention group receiving structured autogenic relaxation followed by murottal therapy and a control group receiving standard care with music listening. Anxiety, sleep quality, and hemodynamic parameters will be measured at baseline and after a 6-week intervention period. The findings are expected to support the use of non-pharmacological and spiritual-based interventions in improving psychological and physiological outcomes in hemodialysis patients.",[60,61,62],"Chronic Kidney Disease Stage V","End-Stage Renal Disease","Hemodialysis",[64,65,66,67,68],"Autogenic Relaxation","Murottal Therapy","Anxiety","Sleep Quality","Hemodynamics","2026-02-11",{"date":71,"type":37},"2026-02-17",{"date":73,"type":21},"2026-03-01",{"date":75,"type":21},"2026-06-30",{"name":43,"class":44},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":97,"locationsCount":45},"100624127","head-up-position-and-murottal-therapy-in-stroke-patients-100624127","NCT07405593","Head Up Position and Murottal Therapy in Stroke Patients","The Combination Model of 30 Degree Head Up and Murottal Therapy on Blood Pressure, Pulse Rate, Respiratory Rate, Pain Degree, and Projectile Vomiting in Stroke Patients","Inclusion Criteria :\n\n1. Patients with a medical diagnosis of stroke (hemorrhagic and non-hemorrhagic).\n2. Patients with systolic blood pressure above 150 mmHg.\n3. Somnolence (GCS ≥ 9).\n4. Muslim.\n5. Patients without hearing impairment.\n6. Willingness to participate and sign informed consent.\n\nExclusion criteria :\n\n1. Patients who are non-Muslim.\n2. Patients with decreased consciousness (GCS \\\u003C 9).\n3. Patients with heart problems.\n4. Patients with psychiatric disorders.\n5. Patients receiving sedative therapy during the study.",{"count":85,"type":21},112,[24],"This study aims to evaluate the effects of a combination of a 30-degree head-up position and murottal therapy on physiological and symptom outcomes in stroke patients. The intervention is expected to influence blood pressure, pulse rate, respiratory rate, pain level, and the incidence of projectile vomiting. Stroke patients will receive standard care with the addition of the combined intervention. The results of this study may support non-pharmacological nursing interventions to improve patient comfort and clinical stability.",[89],"Stroke",[91,65],"Head Up","2026-02-04",{"date":94,"type":37},"2026-02-12",{"date":73,"type":21},{"date":75,"type":21},{"name":43,"class":44},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":106,"maxAge":54,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100616174","combined-bitter-melon-extract-and-snakehead-fish-powder-supplementation-for-glycemic-control-in-type-2-diabetes-100616174","NCT07302178","Combined Bitter Melon Extract and Snakehead Fish Powder Supplementation for Glycemic Control in Type 2 Diabetes","Effect of Combined Bitter Melon (Momordica Charantia L.) Extract and Snakehead Fish (Channa Striata) Powder Supplementation on Glycemic Status in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Trial","BM-SF Glycemia","Inclusion Criteria:\n\n* Diagnosed with Type 2 Diabetes Mellitus (DMT2).\n* Fasting plasma glucose ≥ 126 mg\u002FdL and ≤ 200 mg\u002FdL or random blood glucose between 200-300 mg\u002FdL.\n* Age 20-65 years\n* Duration of diabetes 0-15 years.\n* Currently using one class of oral antidiabetic medication (biguanide: metformin).\n* Willing to participate and sign written informed consent.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding; or having impaired kidney or liver function (serum creatinine \\> 1.5 mg\u002FdL; SGOT\u002FSGPT \\> 2× upper limit).\n* Allergy to snakehead fish powder (Channa striata) or bitter melon extract (Momordica charantia).\n* Using antidiabetic medications other than metformin, or unable\u002Funwilling to comply with study procedures.","20 Years",{"count":108,"type":21},80,[24],"Type 2 diabetes mellitus (T2DM) remains a major global health problem due to its high prevalence, long-term complications, and substantial economic burden. Conventional antidiabetic therapies, including insulin and oral hypoglycemic agents, may cause significant side effects during long-term use and are contraindicated in certain clinical conditions. Therefore, safe and effective herbal-based alternatives are needed.\n\nPrevious preclinical and early clinical studies have shown that bitter melon (Momordica charantia L.) and snakehead fish (Channa striata) possess antidiabetic and anti-inflammatory properties, including improvement in glucose regulation, stimulation of insulin secretion, and regeneration of pancreatic cells. However, clinical evidence on their combined use remains limited.\n\nThis randomized, double-blind, placebo-controlled clinical trial aims to evaluate the effect of daily supplementation with a combination of bitter melon extract and snakehead fish powder on glycemic status in adults with Type 2 diabetes mellitus. Ninety eligible participants will be randomly assigned to a treatment group receiving 500 mg\u002Fday of the herbal combination or a placebo for 4 weeks. Glycemic status will be assessed primarily through glycated albumin (GA) levels.\n\nThe findings of this study are expected to provide scientific evidence regarding the safety and efficacy of this herbal combination as a complementary antidiabetic therapy.",[112,113],"Type 2 Diabetes Mellitus (T2DM)","Hyperglycemia",[115,116,117,118],"Bitter melon extract","Momordica charantia","Channa striata","Glycemic status","2025-12-11",{"date":121,"type":37},"2025-12-24",{"date":123,"type":21},"2026-01-01",{"date":125,"type":21},"2026-06-01",{"name":43,"class":44},""]